Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.
Renal cell carcinoma is the most common tumor of the kidney. It has an unpredictable behavior and poor response to systemic therapy. Developing newer therapy for this disease is a priority considering the high recurrence rate and the small subset of patients who benefit from the use of cytokines such as interferon-alpha or interleukin-2. Identifying molecular targets and targeting various biomarkers has revolutionized the therapeutic approach to advanced and metastatic renal cell carcinoma. Although some of the antiangiogenic agents and receptor tyrosine kinase inhibitors appear promising, further understanding of their mechanism of action and the patient population who would benefit most from such agents is still being explored. As numerous targeted agents are entering the clinical investigation arena in a relatively short period of time, newer challenges in renal cell carcinoma therapeutics are emerging. Some of the future challenges in using targeted antineoplastic agents in renal cell carcinoma will include evaluating their long-term safety and benefit, using the particular drug in the appropriate patient population after appropriate stratification and studying the combination of some of these drugs for synergy or additive effects.
Shaheen
Philip E
PE
Fellow, Department of Experimental Therapeutics, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Bukowski
Ronald M
RM
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D003131:Combined Modality Therapy; D016207:Cytokines / Q000627:therapeutic use; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000188:drug therapy*; D011379:Prognosis
D000970:Antineoplastic Agents; D016207:Cytokines; D015507:Drugs, Investigational